ArticleCardiovascular and interventional radiology2024
Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study.
Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03527589 (A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres
Who cites it
10 citing papers in PubMed.
- Evaluation of prostate artery embolization for benign prostatic hyperplasia.International urology and nephrology · 2026Article
- Review
- Prostatic Artery Embolization Using Ethylene Vinyl Alcohol Copolymer (EVOH): Efficacy, Safety and Clinical Impact of Liquid Embolic Penetration.Cardiovascular and interventional radiology · 2026Article
- Disease Progression and Outcomes in Patients With Benign Prostatic Hyperplasia: Protocol for a Multicenter Retrospective Cohort Study.JMIR research protocols · 2026Article
- Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results.La Radiologia medica · 2026Article
- Prostatic Artery Embolization with Cyanoacrylate Glue for Benign Prostatic Hyperplasia: A Systematic Review and Single-arm Meta-analysis of Short-term Outcomes.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Review
- Prostate Artery Embolization vs. Holmium Laser Enucleation of the Prostate: A Matched Pair Analysis of Functional Outcomes and Complications.Journal of clinical medicine · 2025Article
- N-butyl cyanoacrylate glue application in prostate artery embolization for benign prostatic hyperplasia: a systematic review of safety and efficacy.CVIR endovascular · 2025Review
- Prostatic Artery Embolization Using Ethylene Vinyl Alcohol (EVOH) Copolymer for Benign Prostatic Hyperplasia: Twelve-Month Analysis.Cardiovascular and interventional radiology · 2025Article
- Photon counting detector CTA for prostate artery embolization pre-procedure planning and intra-procedural guidance.CVIR endovascular · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe clinical outcomes among patients with benign prostatic hyperplasia (BPH) 24 months following prostatic artery embolization (PAE). MATERIALS AND
methodsThis was an international, multicenter, prospective trial of males with BPH with lower urinary tract symptoms (LUTS) or acute urinary retention (AUR) treated with PAE. The primary outcome was the 12 month change in the International Prostate Symptom Score (IPSS) for patients referred for bothersome LUTS, or urinary catheter independence for patients treated for AUR. Secondary outcome measures included changes in IPSS at 3 and 24 months, changes in quality of life (QoL), changes in the Sexual Health Inventory for Men (SHIM) questionnaire, technical success rate, and adverse events (AEs). Data were summarized using descriptive statistics.
resultsFour hundred seventy-eight consecutive patients underwent PAE (bothersome LUTS: N = 405; AUR: N = 73), mean age was 70 years. For patients treated for bothersome LUTS, mean total IPSS at baseline was 21.8 and decreased to 9.3, 10.6, and 11.2 at 3, 12, and 24 months following PAE, respectively (all p < 0.001); QoL at baseline was 4.7 and decreased to 2.0, 2.1, and 2.3 at 3, 12, and 24 months, respectively (all p < 0.001). The mean SHIM score at baseline and 12 months following PAE was 13.8 and 13.9, respectively. Of the 73 patients treated for AUR, 48 (65.8%) had their indwelling catheter removed within 3 months of PAE and remained catheter free at 24 months. Fifty-five patients (11.5%) experienced ≥ 1 AE and 10 (2.1%) experienced a serious AE.
conclusionPAE is a safe and effective treatment for symptomatic BPH and LUTS. Level of Evidence Level 3 Trial registration ClinicalTrials.gov NCT03527589.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.